Enhancing Oral Bioavailability of Simvastatin Using Uncoated and Polymer-Coated Solid Lipid Nanoparticles
Pharmaceutics · 04.06.2024 · 16 (6) · 763
DOI: 10.3390/pharmaceutics16060763 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 04.06.2024. Verfasst von Amira E Abd-Elghany und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia 61519, Egypt. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Deanship of Scientific Research at King Khalid University, the Deanship of Research and Graduate Studies at King Khalid University.
Abstract (Originalsprache)
Simvastatin (SVA) is a well-prescribed drug for treating cardiovascular and hypercholesterolemia. Due to the extensive hepatic first-pass metabolism and poor solubility, its oral bioavailability is 5%. Solid lipid nanoparticles (SLNs) and hydrogel-coated SLNs were investigated to overcome the limited bioavailability of SVA. Four different lipids used alone or in combination with two stabilizers were employed to generate 13 SLNs. Two concentrations of chitosan (CS) and alginate (AL) were coating materials. SLNs were studied for particle size, zeta potential, in vitro release, rheology, and bioavailability. The viscosities of both the bare and coated SLNs exhibited shear-thinning behavior. The viscosity of F11 (Chitosan 1%) at 20 and 40 rpm were 424 and 168 cp, respectively. F11 had a particle size of 260.1 ± 3.72 nm with a higher release; the particle size of F11-CS at 1% was 524.3 ± 80.31 nm. In vivo studies illustrated that F11 had the highest plasma concentration when compared with the SVA suspension and coated chitosan (F11 (Chitosan 1%)). Greater bioavailability is measured as (AUC0→24), as compared to uncoated ones. The AUC for F11, F11-CS 1%, and the SVA suspension were 1880.4, 3562.18, and 272 ng·h/mL, respectively. Both bare and coated SLNs exhibited a significantly higher relative bioavailability when compared to that from the control SVA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
- Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62223, Saudi Arabia.
ORCID-Profile: Adel Al Fatease, Ali H Alamri, Hamdy Abdelkader
Förderung
- the Deanship of Scientific Research at King Khalid University
- the Deanship of Research and Graduate Studies at King Khalid University
Zitieren
APA
Abd-Elghany, A. E., El-Garhy, O., Fatease, A. A., Alamri, A. H., & Abdelkader, H. (2024). Enhancing Oral Bioavailability of Simvastatin Using Uncoated and Polymer-Coated Solid Lipid Nanoparticles. Pharmaceutics, 16(6), 763. https://doi.org/10.3390/pharmaceutics16060763
Vancouver
Abd-Elghany AE, El-Garhy O, Fatease AA, Alamri AH, Abdelkader H. Enhancing Oral Bioavailability of Simvastatin Using Uncoated and Polymer-Coated Solid Lipid Nanoparticles. Pharmaceutics. 2024;16(6):763. doi:10.3390/pharmaceutics16060763
BibTeX
@article{AbdElghany2024,
author = {Abd-Elghany, Amira E and El-Garhy, Omar and Fatease, Adel Al and Alamri, Ali H and Abdelkader, Hamdy},
title = {Enhancing Oral Bioavailability of Simvastatin Using Uncoated and Polymer-Coated Solid Lipid Nanoparticles},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {6},
pages = {763},
doi = {10.3390/pharmaceutics16060763}
}
EUVIMED